Investigational Drug Information for Tavapadon
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Tavapadon?
Tavapadon is an investigational drug.
There have been 9 clinical trials for Tavapadon.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 13th 2019.
The most common disease conditions in clinical trials are Parkinson Disease, Renal Insufficiency, and Liver Diseases. The leading clinical trial sponsors are Cerevel Therapeutics, LLC and [disabled in preview].
There are eleven US patents protecting this investigational drug and seventy-nine international patents.
Summary for Tavapadon
| US Patents | 11 |
| International Patents | 79 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2019-12-13) |
| Vendors | 15 |
Recent Clinical Trials for Tavapadon
| Title | Sponsor | Phase |
|---|---|---|
| Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease | Cerevel Therapeutics, LLC | Phase 1 |
| Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants | Cerevel Therapeutics, LLC | Phase 1 |
| To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | Cerevel Therapeutics, LLC | Phase 1 |
Clinical Trial Summary for Tavapadon
Top disease conditions for Tavapadon
Top clinical trial sponsors for Tavapadon
US Patents for Tavapadon
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tavapadon | See Plans and Pricing | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| Tavapadon | See Plans and Pricing | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (New York, NY) | See Plans and Pricing |
| Tavapadon | See Plans and Pricing | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| Tavapadon | See Plans and Pricing | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | OncoTherapy Science, Inc. (Kanagawa, JP) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tavapadon
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tavapadon | Argentina | AR096748 | 2033-06-27 | See Plans and Pricing |
| Tavapadon | Australia | AU2014300673 | 2033-06-27 | See Plans and Pricing |
| Tavapadon | Brazil | BR112015030101 | 2033-06-27 | See Plans and Pricing |
| Tavapadon | Canada | CA2916653 | 2033-06-27 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
